Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in ...
PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)- …